Target intelligence / Profile preview

Orai1 (ORAI calcium release-activated calcium modulator 1); STIM1 (stromal interaction molecule 1) (Orai1; STIM1)

Target
Orai1; STIM1
Molecular classification
Ion channel (Orai1 forms the Ca2+-selective pore)
01

Overview

Orai1 is a plasma membrane protein that forms the pore of highly Ca2+-selective store-operated calcium entry (SOCE) channels, activated when the endoplasmic reticulum Ca2+ sensor STIM1 oligomerizes and binds to Orai1 upon ER store depletion. This interaction occurs at ER-plasma membrane junctions, where STIM1's CRAC activation domain (CAD) or SOAR engages Orai1's cytosolic C-terminal and N-terminal regions, triggering a cooperative wave of conformational changes across Orai1's four transmembrane domains to open the central pore lined by TM1. Orai1 channels exhibit extreme Ca2+ selectivity and mediate essential calcium influx for cellular processes like gene transcription, exocytosis, immune responses, and T-cell activation. STIM1, a single-pass ER membrane protein with luminal EF-hand and SAM domains, detects store depletion and links it to Orai1 gating. Dysfunctions, including loss-of-function mutations in Orai1 causing severe combined immunodeficiency (SCID) and gain-of-function mutations linked to tubular aggregate myopathy and Stormorken syndrome, underscore their roles in immunity and muscle function. Therapeutically, modulating Orai1/STIM1 is explored for immune disorders and inflammation, though challenges arise from the channel's allosteric gating and disease-associated mutations.

Other names
CRAC channel subunit (for Orai1)SOCE (store-operated calcium entry) components
02

Mechanism of action

Allosteric activation by STIM1 binding to Orai1 C-terminus and N-terminus, inducing conformational changes in transmembrane domains to open the Ca2+ pore

03

Biological functions

Signal transductionCalcium signalingStore-operated Ca2+ entry
04

Disease associations

Tubular aggregate myopathyStormorken syndromeImmune disorders (e.g., SCID from Orai1 mutations)Inflammation
05

Safety considerations

Gain-of-function mutations cause constitutive channel activity leading to muscle disordersLoss-of-function mutations impair immune functionHigh cooperativity in gating may lead to off-target effects or incomplete blockade
06

Interacting drugs

2-APB (modulates Orai channels)

Beyond the preview

Go deeper on Orai1 (ORAI calcium release-activated calcium modulator 1); STIM1 (stromal interaction molecule 1) (Orai1; STIM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orai1 (ORAI calcium release-activated calcium modulator 1); STIM1 (stromal interaction molecule 1) (Orai1; STIM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call